[翻译文章] 心血管疾病患者的药物护理风险分层工具
Anna de Dios Lopez1, Esther Vicente Escrig2, Paloma Sempere Serrano3
1Farmacia Hospitalaria, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
概括
一个新的工具对心血管疾病患者进行了分层,以提供量身定制的药物护理. 这有助于优化医疗保健资源,通过根据临床和治疗因素识别需要密集干预的人来优化医疗保健资源.
科学领域:
- 心脏病学 心脏病学
- 医药护理 医药护理 医药护理
- 医疗保健服务研究 医疗服务研究
背景情况:
- 心血管疾病 (CVD) 管理需要个性化的药物方法.
- 有效的风险分层对于优化心血管疾病患者的药物护理提供至关重要.
研究的目的:
- 开发和试验一种风险分层工具,用于心血管疾病患者的药物护理.
- 确定需要全面和个性化药物干预的患者.
主要方法:
- 由专门从事心血管风险的医院药剂师合作开发.
- 利用研讨会和试点研究来识别和权衡四个维度的变量.
- 采用凯泽永久的金字塔模型将患者分为三个优先级 (1,2,3).
主要成果:
- 开发了一个20个变量问卷,分组为人口,社会健康,临床和治疗因素.
- 确定的切线点:优先级1 (≥23分),优先级2 (17-22分),优先级3 (<16分).
- 临床和与治疗相关的因素占总得分的80%以上,指导量身定制的干预措施.
结论:
- 开发的工具有效地识别了需要更高水平的药物护理的心血管患者.
- 这有助于更好地调整医疗保健能力和资源分配.
- 为了更广泛的适用性,建议在代表性人口中进一步验证.
相关概念视频
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380
Heart Failure IV: Classification and Diagnostic Evaluation
293
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
293
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
370
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
370
Coronary Artery Disease V: Interprofessional Care
203
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
203
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293


